In Vitro Cellular Toxicology Instead of Using Animals

Votes: 1
Views: 1825
Medical

Superlative BioSciences Corp's Cellular Toxicology Service – WHY:

Increasing governments' support to decrease or stop the testing of possible toxic compounds in animals.

Decrease in vivarium and experiments' costs by reducing the use of animals in toxicology testing.

The above are significant factors that will propel the in vitro toxicology market forward worldwide.

The global In-Vitro Toxicology Market is estimated to be 17.2 billion USD in 2018 with a CAGR of 14%.

Our model is to develop, validate, and run an in vitro toxicology service for a fee to clients in the pharmaceuticals, biopharma, and cell & gene products industries.

Secondary markets are agricultural, cleaning products & consumer goods.

Our first systems will high-throughput in vitro toxicology systems utilizing human umbilical cord and placental derived stem cells for developmental toxicology.

In addition to developmental toxicology, we will develop 3-D cell culture systems representative of various normal and compromised human tissue microenvironments to meet the needs of our clients in the areas of target discovery, drug efficacy testing, and drug safety.

Voting

Voting is closed!

  • ABOUT THE ENTRANT

  • Name:
    Joseph Tarsio
  • Type of entry:
    individual
  • Profession:
    Scientist
  • Number of times previously entering contest:
    1
  • Joseph is inspired by:
    We provide superlative biosciences services such as our Stem Cellular Toxicology Service - Animal-free & based on human umbilical cord and placental stem cells in tissue culture.
  • Patent status:
    pending